Mizuho downgraded Exact Sciences(EXAS) to Neutral from Outperform with a price target of $105, up from $85. The firm cites Abbott’s (ABT) agreement to acquire Exact Sciences for $105 per share in cash for the downgrade. Mizuho sees minimal regulatory push-back to the deal and expects it to close on time by Q2.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences Sets February 20, 2026 Virtual Meeting for Shareholder Vote on $105-per-Share Abbott Merger
- Abbott price target lowered to $152 from $157 at Goldman Sachs
- Evercore ISI upgrades four, downgrades six in MedTech and Tools
- Exact Sciences downgraded to In Line from Outperform at Evercore ISI
- Exact Sciences Approves Executive Bonus Acceleration Amid Abbott Merger